Image 8313926 11055193

Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 5.82 -4.28% -0.26
BCRX closed down 4.28 percent on Tuesday, June 27, 2017, on 42 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Jun 27 Fell Below 50 DMA Bearish 0.00%
Jun 27 Downside 200 DMA Break Bearish 0.00%
Jun 27 New Uptrend Bullish 0.00%
Jun 26 200 DMA Support Bullish -4.28%
Jun 26 Stochastic Reached Overbought Other -4.28%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.25
52 Week Low 2.8
Average Volume 1,906,904
200-Day Moving Average 5.9688
50-Day Moving Average 5.8578
20-Day Moving Average 5.63
10-Day Moving Average 5.868
Average True Range 0.3911
ADX 25.25
+DI 28.42
-DI: 15.3
Chandelier Exit (Long, 3 ATRs) 5.4967
Chandelier Exit (Short, 3 ATRs) 6.2233
Upper Bollinger Band 6.2083
Lower Bollinger Band 5.0517
Percent B (%b) 0.66
Bandwidth 0.205435
MACD Line 0.0451
MACD Signal Line -0.0335
MACD Histogram 0.0786